Streetbeat News

NRXP

NRx Pharmaceuticals, Inc.

https://www.nrxpharma.com

Industry

Biotechnology

NRX Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. Its products include ZYESAMI, an investigational drug that has completed a Phase IIb/III clinical study for COVID-19 related respiratory failure; and NRX-100 and NRX-101 oral therapeutics for the treatment of bipolar depression in patients with acute suicidal behavior/ideation and sub-acute suicidal ideation and behavior. The company was founded in 2015 and is based in Wilmington, Delaware.

Open

2.09

Mkt cap

40M

Volume

242K

High

2.40

P/E Ratio

-1.11

52-wk high

6.01

Low

2.08

Div yield

N/A

52-wk low

1.10

Asana, Inc. (ASAN) shares fell by 11% following soft FY25 revenue guidance, despite beating quarterly earnings and sales estimates. Other stocks showed significant movement, with ClearOne, Inc. (CLRO) and Regulus Therapeutics Inc. (RGLS) among the top gainers, while BYND Cannasoft Enterprises Inc. (BCAN) and Simpple Ltd. (SPPL) led the losers. The market saw a mix of positive and negative financial results, strategic moves, and guidance updates.

Portfolio Pulse from Avi Kapoor

March 12, 2024 | 6:07 pm

In Tuesday's intraday session, several healthcare stocks experienced significant movements. Regulus Therapeutics (RGLS) led the gainers with a 94.9% increase, while Lexaria Bioscience (LEXX) saw the largest decline at 30.5%. Other notable movers included Bright Green (BGXX), SCWorx (WORX), and Caribou Biosciences (CRBU), among others. The movements were attributed to various factors, including quarterly earnings reports for Viracta Therapeutics (VIRX) and Caribou Biosciences.

Portfolio Pulse from Benzinga Insights

March 12, 2024 | 5:31 pm

NRx Pharmaceuticals is considering a reverse stock split to maintain its NASDAQ listing compliance, leading to a decrease in its share price.

Portfolio Pulse from Benzinga Newsdesk

March 12, 2024 | 4:30 pm

Nasdaq Composite gained around 1% amid positive U.S. stock market movements. ClearOne, Inc. announced a special cash dividend, causing shares to surge 120%. Regulus Therapeutics and Ranpak Holdings also saw significant gains following positive announcements. Conversely, BYND Cannasoft, Blade Air Mobility, and NRx Pharmaceuticals experienced sharp declines due to various negative developments. The U.S. consumer price index for February 2024 indicated higher-than-expected inflation rates.

Portfolio Pulse from Avi Kapoor

March 12, 2024 | 4:10 pm

U.S. stocks traded higher with the Dow gaining 0.27% and the Nasdaq up by 0.69% amid news of U.S. inflation rate rising to 3.2% in February, surpassing expectations. ClearOne, Regulus Therapeutics, and Ranpak Holdings reported significant stock movements due to corporate announcements, while BYND Cannasoft, Blade Air Mobility, and NRx Pharmaceuticals saw declines.

Portfolio Pulse from Avi Kapoor

March 12, 2024 | 2:11 pm

In Tuesday's pre-market session, several healthcare stocks showed significant movement. Regulus Therapeutics led the gainers with an 84.8% increase, while Renalytix faced the largest drop among the losers, declining by 27.2%. Notably, Bioventus and CytomX Therapeutics released their Q4 earnings, influencing their stock prices.

Portfolio Pulse from Benzinga Insights

March 12, 2024 | 1:06 pm

NRx Pharmaceuticals is considering a reverse stock split to comply with Nasdaq listing requirements. This action may also involve a change in the company's name and CUSIP number. Additionally, the company has hired attorneys to address and prevent naked short positions in its securities.

Portfolio Pulse from Benzinga Newsdesk

March 12, 2024 | 11:57 am

NRx Pharmaceuticals, Inc. (NRXP) and its subsidiary HOPE Therapeutics have completed a Memorandum of Understanding with Conversio Health and established a partnership with Nephron Pharmaceuticals for the distribution of IV Ketamine. This collaboration aims to provide a consistent supply of high-quality, FDA- and DEA-compliant IV ketamine to patients and clinics nationwide. The company is preparing for the initial sale of ketamine by the end of March 2024 and plans to file a New Drug Application (NDA) for HTX-100, with a potential launch in early 2025.

Portfolio Pulse from Benzinga Newsdesk

March 11, 2024 | 12:36 pm

In Friday's after-market session, several healthcare stocks showed notable movements. Talphera's shares surged by 15.6% following its Q4 earnings report. Other gainers included Genelux, Estrella Immunopharma, Inspire Veterinary, NRX Pharmaceuticals, and Fortrea Holdings with increases ranging from 5.02% to 10.06%. Conversely, Atara Biotherapeutics led the losers, dropping by 9.4%, followed by declines in ProKidney, Mira Pharmaceuticals, Yield10 Bioscience, GeneDx Hldgs, and Envoy Medical.

Portfolio Pulse from Benzinga Insights

March 08, 2024 | 9:31 pm

Nrx Pharmaceuticals has entered into a definitive purchase agreement to sell 2.7 million shares at $0.38 per share, causing its stock to trade higher.

Portfolio Pulse from Benzinga Newsdesk

March 01, 2024 | 4:00 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.